Cellectis S.A. CLLS
1.41 USD +0.30 (+27.03%)
Nov 11, 2026, 1:04 PM EST
1.27 Day range 1.53
0.881 52-week range 5.45
- YTD
- -70.87%
- 1 year
- -62.10%
News
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Lisata Therapeutics (NASDAQ:LSTA) stock rose 37.2% to $1.4 during Wednesday's regular session. The market value of their outstanding shares is at $11.0 million. BioStem Technologies…
globenewswire.com Cellectis to Report Third Quarter Financial Results on November 12, 2026 NEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a genome engineering company developing genetic medicines for diseases that today demand…
benzinga.com This Nu Holdings Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday Analysts downgraded NU, BAK, CLLS and CBZ; price targets for NU, BAK and CLLS were cut sharply.
benzinga.com Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday Analysts raised targets for RAPP, ALLR, UNP and ALVO; cut targets for NU, CLLS and JBHT, with several rating upgrades and downgrades.
benzinga.com Barclays Downgrades Cellectis to Underweight, Lowers Price Target to $1.3 Barclays analyst Lukas Shumway downgrades Cellectis (NASDAQ:CLLS) from Overweight to Underweight and lowers the price target from $9 to $1.3.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers DataMEDS AI (NASDAQ:MEDS) shares rose 124.1% to $3.63 during Wednesday's pre-market session. The company's market cap stands at $4.9 million. Tempest Therapeutics (NASDAQ:TPST) stock moved…
benzinga.com This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday Analysts downgraded Banco Santander Brasil, Ribbon Communications, Cellectis, Scholar Rock, with mixed price-target changes.
benzinga.com Wells Fargo Maintains Equal-Weight on Cellectis, Lowers Price Target to $3 Wells Fargo analyst Yanan Zhu maintains Cellectis (NASDAQ:CLLS) with a Equal-Weight and lowers the price target from $4 to $3.- benzinga.com Baird Maintains Outperform on Cellectis, Lowers Price Target to $8 Baird analyst Jack Allen maintains Cellectis (NASDAQ:CLLS) with a Outperform and lowers the price target from $10 to $8.
benzinga.com Why Veea Shares Are Trading Higher By 58%; Here Are 20 Stocks Moving Premarket Veea shares surged 58% premarket on a NovaGen merger plan and $10M GeoNova investment, while other stocks posted notable gains and losses.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Basel Medical Group (NASDAQ:BMGL) shares moved upwards by 59.8% to $7.32 during Monday's regular session. Scinai Immunotherapeutics (NASDAQ:SCNI) stock increased by 45.18% to $2.41. The…
benzinga.com Crude Oil Jumps 3%; Corning Shares Move Lower U.S. stocks fell Monday as tech slid; Nvidia may invest $10B in Anthropic’s IPO. Oil rose 3%, while gold, silver and copper declined.
benzinga.com Nasdaq Down Over 200 Points; Cellectis Shares Plunge U.S. stocks fell Monday, led by a 2% tech decline. Nvidia may invest $10B in Anthropic; oil jumped 4.2%, while European markets mostly slipped.
benzinga.com Cellectis Pivots to Gene Editing in Major Overhaul Cellectis (NASDAQ: CLLS) pivots to in vivo gene editing, extending cash runway to H2 2028. Read pipeline updates on .HEAL-101 & .HEAL-201.- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) stock moved upwards by 44.6% to $2.4 during Monday's pre-market session. The company's market cap stands at $1.1 million. Definium Therapeutics…
benzinga.com Corning, Cellectis, Biodexa Pharmaceuticals And Other Big Stocks Moving Lower In Monday’s Pre-Market Session U.S. stock futures fell, with Nasdaq 100 futures down 500 points. Corning dropped 8% after a $2B offering; several other stocks also slid premarket.
benzinga.com Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket Scholar Rock surged 11.9% after FDA approved ISEMBYLD for SMA; Scinai, Intercont and Rum led premarket gainers, while Picocela fell.
benzinga.com Cellectis Exits Lasme-Cel And Eti-Cel Development To Focus On In Vivo Gene Editing Pipeline, Targeting Cash Runway Extension Into H2 2028 Cellectis to advance two lead in vivo programs .HEAL-101 and .HEAL-201 in severe dyslipidemias with preliminary Phase 1 data planned in H2 2027 and H1 2028, respectivelyTransformation supported by…
benzinga.com Cellectis Q2 Adj. EPS $(0.19) Beats $(0.27) Estimate, Sales $6.904M Miss $13.225M Estimate Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.27) by 29.63 percent. This is a 13.64 percent increase over losses of $(0.22)…- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com Cellectis Secures FDA Regenerative Medicine Advanced Therapy Designation For lasme-cel, CD22-Targeting Allogeneic CAR-T Cell Therapy Product Candidate, For Treatment Of r/r B-ALL Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that the…- benzinga.com Barclays Initiates Coverage On Cellectis with Overweight Rating, Announces Price Target of $9 Barclays analyst Lukas Shumway initiates coverage on Cellectis (NASDAQ:CLLS) with a Overweight rating and announces Price Target of $9.
- benzinga.com Cellectis To Present Phase 1 CAR-T Data For Lasme-cel And Eti-cel At EHA 2026, Highlighting Early Safety, Response Signals And Ongoing Pivotal Programs Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced upcoming…
- benzinga.com Cellectis Q1 Adj. EPS $(0.16) Beats $(0.27) Estimate, Sales $7.548M Miss $12.267M Estimate Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.27) by 40.74 percent. This is a 5.88 percent increase over losses of $(0.17)…
benzinga.com Earnings Scheduled For May 11, 2026 
benzinga.com Cellectis Presents New Research On TALE-Based Epigenetic Editing Approach At ASGCT Annual Meeting Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today presents new research…- benzinga.com Citizens Reiterates Market Outperform on Cellectis, Maintains $8 Price Target Citizens analyst Silvan Turkcan reiterates Cellectis (NASDAQ:CLLS) with a Market Outperform and maintains $8 price target.
benzinga.com Allogene Therapeutics Stock Hits 52-Week High - Here's Why Allogene's ALPHA3 trial shows strong MRD clearance and ctDNA reduction, signaling potential to delay relapse in lymphoma patients.
benzinga.com Leggett & Platt, Allogene Therapeutics, Revolution Medicines And Other Big Stocks Moving Higher On Monday U.S. stocks were mixed on Monday, with the Dow Jones falling over 200 points. Leggett & Platt rose on news of being acquired by Somnigroup.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session - benzinga.com Earnings Scheduled For March 19, 2026
benzinga.com This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday 
benzinga.com Lightwave Logic, Kyverna Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com Earnings Scheduled For November 7, 2025 
benzinga.com Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session 
benzinga.com Enerpac Tool Group Posts Upbeat Results, Joins Praxis Precision Medicines, J B Hunt, Salesforce And Other Big Stocks Moving Higher On Thursday 
benzinga.com Top 2 Health Care Stocks That May Keep You Up At Night This Month 
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday's pre-market session. The market value of their outstanding shares is at $10.5 million.
benzinga.com Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Monday. Shares of Inventiva ADR (NASDAQ: IVA) fell sharply in today's pre-market trading following H1…
benzinga.com Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announced plans to acquire Merus for $8 billion in all-cash deal adding breakthrough therapy Petosemtamab to its…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session - benzinga.com Earnings Scheduled For August 4, 2025
benzinga.com Why Celestica Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com Earnings Scheduled For May 12, 2025
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com Why Rubrik Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket